Xencor Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect the nine nominees named in the proxy statement to the Board of Directors to serve until the next annual meeting and until their successors are duly elected and qualified.

2. 2

   Ratification of Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Approval of Amendment to the Amended and Restated 2023 Equity Incentive Plan to Increase Authorized Shares by 4,000,000

   ManagementBoard: FOR

   Approve an amendment to the Amended and Restated 2023 Equity Incentive Plan to increase the number of authorized shares available for issuance thereunder by 4,000,000 shares.

   More detail

   This management proposal asks shareholders to approve an amendment to the Company’s Amended and Restated 2023 Equity Incentive Plan to add 4,000,000 shares to the plan’s existing share reserve. Management and the Human Capital Management & Compensation Committee state the increase is intended to provide sufficient shares to support approximately one year of routine equity grant activity and to remain competitive for talent in the biotechnology sector. The proposal is transaction-agnostic and does not change other substantive plan terms; it only increases the fixed share reserve (the Amended 2023 Plan retains anti-repricing protections, no evergreen feature, limits on director compensation, and other governance-oriented features). The Board frames the request as necessary because, based on current grant practices and historical burn rate (~4.97% average for 2023–2025), the existing reserve would likely be insufficient by the next planned annual grant date. Management discloses current outstanding awards and the remaining available shares and quantifies resulting overhang and dilution metrics, which were considered in sizing the increase. The Board’s recommendation is driven by retention and recruitment considerations and by an assessment of cash runway ($610.8M at year-end 2025) that it believes supports continued grant activity; the Board also highlights procedural protections such as requiring shareholder approval for repricings. Key governance implications for shareholders include additional future dilution and the need to monitor burn rate and grant practices; institutional investors will also weigh plan size versus peer practice and company stage. A sophisticated reviewer should evaluate the requested increase relative to the company’s hiring plans, expected grant sizes, historical usage, overhang, and the company’s stated compensation philosophy, and consider whether the company’s stated safeguards (no evergreen, no repricing without approval) and disclosed limits are sufficient to mitigate dilution concerns.

4. 4

   Advisory Vote to Approve Named Executive Officer Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement.

   More detail

   This advisory (non-binding) proposal asks shareholders to approve the Company’s disclosed executive compensation policies and outcomes for its named executive officers (NEOs). Management describes its program as pay-for-performance with a large portion of CEO and other NEO compensation variable and at risk (annual bonus and long-term equity), and discloses metrics such as target award mix, peer benchmarking, burn rate, and governance practices (clawback policy, no repricings without shareholder approval, no single-trigger CIC cash payments or excise tax gross-ups). The Board recommends a vote FOR, citing a history of strong shareholder support (97.9% in 2025) and the view that the program aligns incentives with long-term shareholder value. For investors the vote is advisory; however, the HCMCC commits to consider the outcome when setting future compensation. Relevant considerations include the mix of options versus RSUs (60/40 in 2025), the reliance on equity-driven incentives to conserve cash, the company’s operating milestones and cash runway, and the degree to which corporate goals and performance metrics are transparent and linked to pay. Risk-mitigation features are in place (independent compensation consultant, clawback policy, anti-hedging, and anti-pledging), but sophisticated reviewers should evaluate whether performance goals were sufficiently stretching and whether realized pay is aligned with long-term TSR and company performance. Given the non-binding nature, a FOR vote supports management’s current approach while a significant negative vote would likely prompt the HCMCC to reevaluate plan design and disclosure.

Upcoming shareholder meetings at Xencor Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Xencor Inc 2026 annual meeting?

Xencor Inc (XNCR) holds its 2026 annual shareholder meeting on Tuesday, June 16, 2026.

What is the record date for the Xencor Inc 2026 meeting?

The record date for the Xencor Inc 2026 meeting is Friday, April 17, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Xencor Inc's 2026 meeting?

The board is presenting 9 director nominees at the Xencor Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Xencor Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Xencor Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.